IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Vanguard Total Stock Mkt Idx Inv

Vanguard Institutional 500 Index Trust

The Health Care Select Sector SPDR® ETF

iShares Biotechnology ETF

Vanguard Mid-Cap Growth ETF

Vanguard Institutional Index I

Vanguard Windsor™ II Inv

State St S&P 500® Indx SL Cl III

American Funds IS® Growth-Income 1

Capital Group Core Equity Composite

Blackrock Eq Idx Fund CF

VA CollegeAmerica Amcap 529A

Vanguard Mid Cap Index Institutional

Oakmark Investor

SPDR® S&P 500® ETF Trust

Fidelity 500 Index

iShares Core S&P 500 ETF

Oakmark Select Investor

Vanguard Value Index Inv

Impax Global Opportunities Strategy Comp

Vanguard Group Inc

BlackRock Inc

FMR Inc

Mitsubishi UFJ Asset Management Co.,Ltd

Longview Partners

Cantillon Capital Management LLC

JPMorgan Chase & Co

Impax Asset Management Group PLC

Amvescap Plc.

Goldman Sachs Group Inc

NORGES BANK

Northern Trust Corp

Harris Associates L.P.

State Street Corp

Geode Capital Management, LLC

AllianceBernstein L.P.

Morgan Stanley - Brokerage Accounts

Canada Pension Plan Investment Board

Lazard Asset Management LLC

Farallon Capital Management, L.L.C.

IQVIA Holdings Inc

Mr. Ari  Bousbib

CEO & Chairman

Mr. Ronald E. Bruehlman

Executive VP & CFO

Mr. Eric M. Sherbet J.D.

Executive VP, General Counsel & Secretary

Mr. W. Richard Staub III

President of Research & Development Solutions

Ms. Keriann  Cherofsky

Senior VP, Corporate Controller & Chief Accounting Officer

Mr. Jim  Berkshire

Executive Vice President of Global Technology & Operations

Dr. Jeffrey A. Spaeder M.D.

Senior VP, Global Chief Medical & Scientific Officer

Kerri  Joseph

SVP of Investment Relation & Treasury

Ms. Trudy  Stein

Chief Human Resources Officer & Executive VP

Dr. Cynthia L. Verst

President of Design & Delivery Innovation

IQVIA Holdings Inc (IQV) Stock Analysis, Discussion Forum and Financial Metrics - NYSE Exchange

IQVIA Holdings Inc (IQV) Earnings Report Date and History | NYSE

IQV's next earnings is on February 12, 2025 (Before Market Open)

When is the earnings report for IQV?

IQV Earnings History

IQV Stock Discussion Forum and Message Board

News for NYSE: IQV